Malignant renal tumours incidence and survival in European children (1978–1997): Report from the Automated Childhood Cancer Information System project


      More than 5000 cases of malignant renal tumour diagnosed in children under the age of 15 years during the period 1978–1997 in Europe, were extracted from the database of the Automated Childhood Cancer Information System (ACCIS). In 1988–1997 the age-standardised incidence rate of childhood renal tumours in Europe was 8.8 per million, with significant differences between regions. Wilms’ tumour (WT, M-8960) accounted for 93% of renal tumours and about 7% were bilateral. The incidence rates of WT increased over the 20 years, by 0.7% per year. European 5-year survival for children diagnosed with WT in 1988–1997 was 85%, ranging from 73% in the East to 91% in the North. Patients in the age group 0–3 years at diagnosis had a more favourable prognosis (5-year survival 87%) than those diagnosed later (81%), P < 0.0001. Patients with unilateral WT (n = 2085) had better 5-year survival (85%) than 154 patients with bilateral tumours (76%), P = 0.003. Five-year survival for 64 patients with clear cell sarcoma of kidney was 68%, for 43 patients with rhabdoid tumour of kidney it was 23%, and for 56 patients with renal cell carcinoma it was 87%. For combined European data, 5-year survival for WT increased from 73% in 1978–1982 to 87% in 1993–1997 and the increase was significant in three out of five regions (East, North and West). Further development and exploitation of the ACCIS database will benefit clinical management and aetiological studies.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Parkin DM, Kramárová E, Draper GJ, et al., editors. International incidence of childhood cancer, International Agency for Research on Cancer, International Association of Cancer Registries Vol. II. Lyon: IARC Scientific Publications No. 144; 1998.

      2. Little J, editor. Epidemiology of childhood cancer IARC scientific publications no. 149. Lyon: International Agency for Research on Cancer; 1999.

        • Green D.M.
        Wilms’ tumour.
        Eur J Cancer. 1997; 33: 409-418
        • Knudson Jr, A.G.
        • Strong L.C.
        Mutation and cancer: a model for Wilms’ tumour of the kidney.
        J Natl Cancer Inst. 1972; 48: 313-324
        • Breslow N.E.
        • Norris B.
        • Norkoal P.A.
        • et al.
        Characteristics and outcomes of children with Wilms tumour-aniridia syndrome: a report from the National Wilms’ Tumour Study Group.
        J Clin Oncol. 2003; 21: 4579-4585
        • Rapley E.A.
        • Barfoot R.
        • Bonaiti-Pellie C.
        • et al.
        Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2.
        Br J Cancer. 2000; 83: 177-183
        • Fukuzawa R.
        • Breslow N.E.
        • Morison I.A.
        • et al.
        Epigenetic differences between Wilms’ tumours in white and east-Asian children.
        Lancet. 2004; 363: 446-451
        • D’Angio G.J.
        • Evans A.E.
        • Breslow N.
        • et al.
        The treatment of Wilms’ tumour: results of the national Wilms’ tumour study.
        Cancer. 1976; 38: 633-646
        • Lemerle J.
        • Voûte P.A.
        • Tournade M.F.
        • et al.
        Preoperative versus postoperative radiotherapy, single versus multiple courses of Actinomycin D, in the treatment of Wilms’ tumour. Preliminary results of a controlled clinical trial conducted by the International Society of Pediatric Oncology (SIOP).
        Cancer. 1976; 38: 647-654
        • Pritchard-Jones K.
        • Pritchard J.
        Success of clinical trials in childhood Wilms’ tumour around the world.
        Lancet. 2004; 364: 1468-1470
      3. Bernstein L, Linet M, Smith MA, et al. Renal tumour. In: Ries LAG, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER program. Bethesda: NIH Publication no 99–4649; 1999, p. 79–90.

        • Biegel J.A.
        • Tan L.
        • Zhang F.
        • Wainwright L.
        • et al.
        Alterations of the hSNF5/INI1 gene in central nervous system atypical teratoid/rhabdoid tumors and renal and extrarenal rhabdoid tumors.
        Clin Cancer Res. 2002; 8: 3417-3461
        • Argani P.
        • Antonescu C.R.
        • Illei P.B.
        • et al.
        Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents.
        Am J Pathol. 2001; 159: 179-192
        • Šteliarová-Foucher E.
        • Stiller C.
        • Kaatsch P.
        • et al.
        Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since 1970s: the ACCIS project.
        Lancet. 2004; 364: 2097-2105
        • Plesko I.
        • Kramárová E.
        • Stiller C.A.
        • et al.
        Survival of children with Wilms’ tumour in Europe.
        Eur J Cancer. 2001; 37: 736-743
        • Gatta G.
        • Corazziari I.
        • Magnani C.
        • et al.
        Childhood cancer survival in Europe.
        Ann Oncol. 2003; 14: v119-v127
        • Kramárová E.
        • Stiller C.A.
        The International Classification of Childhood Cancer.
        Int J Cancer. 1996; 68: 759-765
      4. Percy C. Van Holten V. Muir C. International Classification of Diseases for Oncology. 2nd ed. World Health Organisation, Geneva1992
      5. Boyle P, Parkin DM. Statistical methods for registries. In: Jensen OM, Parkin DM, MacLenann R, et al., editors. Cancer registration: principles and methods. IARC scientific publications no. 95. Lyon: International Agency for Research on Cancer, International Association of Cancer Registries; 1991.

      6. Parkin DM, Hakulinen. Analysis of survival. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG. Cancer registration: principles and methods. IARC sci publ no. 95. Lyon: International Agency for Research on Cancer; 1991.

        • Kalbfleisch J.D.
        • Prentice R.L.
        The statistical analysis of failure time data.
        John Wiley & Sons, New York1980
        • Simoni L.
        • Calafell F.
        • Pettener D.
        • et al.
        Geographic patterns of mtDNA diversity in Europe.
        Am J Hum Genet. 2000; 66: 262-278
        • Sauvat F.
        • Sarnaki S.
        • Brisse H.
        • et al.
        Outcome of suprarenal localized masses diagnosed during perinatal period: a retrospective multi-center study.
        Cancer. 2002; 94: 2474-2480
        • Indolfi P.
        • Terenziani M.
        • Casale F.
        • et al.
        Renal cell carcinoma in children: a clinicopathologic study.
        J Clin Oncol. 2003; 21: 530-535
        • Graf N.
        • Tournade M.F.
        • de Kraker J.
        The role of preoperative chemotherapy in the management of Wilms tumour – the SIOP studies.
        Urologic Clinics of North America. 2000; 27: 443-454
        • Tournade M.F.
        • Com-Nourgué C.
        • Voute P.A.
        • et al.
        Results of the Sixth International Society of Pediatric Oncology Wilms’ Tumour Trial and Study: a risk-adapted therapeutic approach in Wilms’ tumour.
        J Clin Oncol. 1993; 11: 1014-1023
        • D’Angio G.J.
        • Evans A.E.
        • Breslow N.
        • et al.
        The treatment of Wilms’ tumour: results of the second National Wilms’ tumour study.
        Cancer. 1981; 47: 2302-2311
        • Pritchard-Jones K.
        • Kelsey A.
        • Vujanic G.
        • et al.
        Older age is an adverse prognostic factor in stage I, favourable histology Wilms’ tumour treated with vincristine monochemotherapy: a study by the United Kingdom Children’s Cancer Study Group, Wilms tumour working group.
        J Clin Oncol. 2003; 21: 3269-3275
        • Green D.M.
        • Beckwith J.B.
        • Weeks D.A.
        • et al.
        The relationship between microsubstaging variables, age at diagnosis, and tumour weight of children with stage I/favorable histology Wilms’ tumour.
        Cancer. 1994; 74: 1817-1820
        • de Kraker J.
        • Graf N.
        • van Tinteren H.
        • et al.
        for the International Society of Paediatric Oncology Nephroblastoma Trial Committee. Reduction of postoperative chemotherapy in children with stage I intermediate risk and anaplasia Wilms’ Tumour. The SIOP 93–01 randomised trial.
        Lancet. 2004; 364: 1229-1235